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Quantitative Assessment of Erythropoiesis and Functional Classification 
of Anemia Based on Measurements of Serum Transferrin Receptor 
and Erythropoietin 
By Yves Beguin, Gisela K. Clemons, Pensri Pootrakul, and Georges Fillet 
We evaluated the quantitative value of a simple model of 
erythropoiesis, based on the basic assumptions that the 
red blood cell (RBC) mass determines erythropoietin (Epo) 
production, which in turn stimulates erythropoietic activity. 
The RBC mass was quantitated by direct isotopic mea- 
surement (RCM), Epo production by serum Epo levels, and 
erythropoiesis by the ferrokinetic measurement of the er- 
ythron transferrin uptake (ETU), the serum transferrin re- 
ceptor (TfR) level, and the reticulocyte (retic) index, and 
was completed by an evaluation of overall marrow erythron 
cellularity. We studied a total of 195 subjects, including 
31 normal individuals, 38 patients with polycythemia, and 
126 patients with various forms of anemia. Instead of only 
quantitating Epo and erythropoiesis in absolute terms, we 
also evaluated them in relation to the degree of anemia or 
polycythemia, and expressed the results as a ratio of ob- 
served values to values predicted from the regression 
equations between hematocrit (Hct) on the one hand, and 
Epo, TfR, and ETU on the other, obtained in a carefully se- 
lected subpopulation. The slope of the regression of TfR 
(as well as ETU) versus Hct was very similar to the slope 
of the regression of Epo versus Hct. Average EPO and TfR 
(as well as ETU) values predicted from the regression equa- 
tions were quite comparable to observed values in most 
RYTHROPOIESIS depends on the proliferative capacity E of erythroid progenitors in the bone marrow (BM) 
and their stimulation by erythropoietin (Epo). Epo pro- 
duction by the kidney is determined by the level of oxygen 
supply, which depends mostly on the red blood cell (RBC) 
mass.’ An inverse relationship has been shown between 
serum Epo levels and hematocrit (Hct).’ Epo stimulates 
RBC production by inducing the proliferation and differ- 
entiation of committed erythroid progenitors. In the pres- 
ence of a normal marrow stem cell reserve, erythropoiesis 
will therefore increase in proportion to the degree of ane- 
mia. On the other hand, polycythemia can originate from 
an autonomous proliferation of marrow erythroid progen- 
itors (polycythemia vera) or be secondary to increased Epo 
production. 
The present study is based on a simple model of the reg- 
ulation of erythropoiesis, ie, that the RBC mass determines 
Epo production, which in turn stimulates erythropoietic ac- 
tivity. Erythropoiesis was quantitated both by the ferrokinetic 
measurement of the erythron transferrin uptake (ETU)3 and 
the determination of plasma transferrin receptor (TW) levels, 
which we recently showed to be a simple quantitative assay 
of total erythropoiesis in rats4 as well as in  human^.^ This 
report is aimed at: (1) quantitating erythropoiesis relative to 
the Hct rather than simply in absolute values; ( 2 )  testing the 
validity of the model for the quantitative assessment of the 
erythropoietic response to Epo; (3) testing the appropriateness 
of a physiologic assessment of RBC disorders based on mea- 
surements of the Hct, retic index, serum Epo, and serum TfR 
in a single blood sample; and (4) examining the association 
between the pathogenesis of disordered erythropoiesis and 
clinical diagnosis. 
groups of subjects, with exceptions predictable from 
knowledge of the pathophysiology of these hematologic 
disorders. We identified four major patterns of erythropoi- 
esis, ie, normal, hyperdestruction (with variants of hemo- 
lysis or ineffective erythropoiesis), intrinsic marrow hypo- 
proliferation, and defective Epo production. Dissecting out 
groups of patients showed much greater heterogeneity than 
when patients were analyzed by group. This was particu- 
larly true in the case of a hypoproliferative component being 
combined with hyperdestruction, giving what we called a 
”mixed disorder of erythropoiesis.” We conclude that the 
pathophysiology of anemia can be assessed by a simple 
measurement of Hct. retic index, Epo, and TfR levels, with 
Epo and TfR being more informative when expressed in 
relation to the degree of anemia. The model is particularly 
useful for detecting the presence of multiple mechanisms 
of anemia in the same patient. However, it has limitations 
inherent to the relative invalidity of TfR in iron deficiency, 
the imprecision of a retic count, and the difficulty in distin- 
guishing hemolysis from ineffective erythropoiesis in some 
patients and in recognizing a component of hyperdestruc- 
tion in hypoproliferative anemia. 
0 1993 by The American Society of Hematology. 
SUBJECTS AND METHODS 
Subjects 
A total of 195 subjects were studied. These included 31 normal 
subjects aged 18 to 76 years, 38 patients with polycythemia (PC), 
and 126 patients with anemia. The clinical diagnosis of PC was based 
on the isotopic measurement of an RBC mass (RCM) greater than 
125% of predicted value: either currently or previously. Among 
polycythemic patients, 9 had polycythemia vera (PV), 12 secondary 
PC, 12 PC of uncertain origin, and 5 relative PC (no history of absolute 
PC and current RCM lower than 125% of predicted value in the 
presence of a reduced plasma volume).6.’ Among anemic patients, 
18 had a myeloproliferative disorder (MPD) (either chronic myelog- 
enous leukemia [CML] or essential thrombocythemia), I O  a myelo- 
dysplastic syndrome (MDS), I8 agnogeneic myeloid metaplasia 
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(AMM), I I hypoplastic/aplastic anemia, 15 chronic renal failure, 11 
0-thalassemia/hemogJobin E, 10 hemoglobin H (HbH) disease, 8 he- 
reditary spherocytosis, and 1 1 autoimmune hemolytic anemia 
(AIHA). In addition, 5 patients with chronic renal failure were re- 
ceiving recombinant human erythropoietin (40 U/K& 3 times a week, 
intravenously [IV] after hemodialysis) and 9 patients had received 
an autologous (N = 4) or allogeneic (N = 5 )  BM transplant (BMT) 
6 to 12 months earlier. Informed consent was obtained from all sub- 
jects. The vast majority of them underwent the procedure as part of 
the routine investigation of their hematologic disorder. Except for 
marrow transplant patients, they were generally in steady state and 
had not received blood transfusions in the preceding 3 months. None 
of the patients was iron deficient, based on a serum femtin level 
higher than 12 ng/mL.* 
Blood Volume (B v) Measurement 
Total BV was the sum of simultaneous measurements of RCM 
and plasma volume. The patient's own plasma or a hepatitis-free 
and acquired immunodeficiency syndrome (AIDS)-free plasma from 
a normal donor was used, depending on the patient's unbound iron- 
binding capacity (UIBC). Ten milliliters of plasma was incubated for 
30 minutes at 37°C with 2 to 3 pCi of 59FeC13 previously mixed with 
4% sodium citrate to ensure a molar ratio of citrate to iron of 50: 1. 
RBCs from 20 mL autologous whole blood were incubated for 30 
minutes at 37°C with 10 to 20 pCi of Na,5'Cr04, washed twice, and 
resuspended in normal saline.' Weighed volumes of the labeled so- 
lutions were set aside for the preparation of diluted standard solutions. 
Weighed amounts of labeled RBCs and plasma were injected into a 
forearm vein and samples were drawn from the other arm. Plasma 
iron (PI) and total iron-binding capacity (TIBC) were measured by 
standard procedures.l0." 59Fe and 5'Cr activities were counted in a 
gamma counter and corrections were made for cross-counting using 
standard solutions. "Fe was occasionally used in place of 59Fe and 
its activity was counted in a liquid scintillation counter. Plasma vol- 
ume and RCM were calculated as: 
where I is the total amount of radioactivity injected, and C is the 
sample activity per milliliter of plasma extrapolated to 0 time or per 
milliliter of RBCs in the 15- to 30-minute sample (60-minute sample 
when delayed mixing was suspected). The observed/predicted (O/P) 
ratio of RCM was calculated.6 
Ferrokinet ic Studies 
formula12: 
PIT (mg/dL whole blood per day) 
The plasma iron turnover (PIT) was calculated from a standard 
- PI (fig/dL) X (100 - Hct X 0.9)/100 
- 
t-1/2 (min) 
where t-% is the clearance half-time of t ran~femn-~~Fe,  and 0.9 the 
correction for trapped plasma in the Hct (0.98) and to convert venous 
Hct to whole body Hct (0.92). 
Extravascular flux, a function of plasma iron concentration,'* was 
then subtracted to obtain tissue iron uptake (TIU): 
TIU (mg/dL whole blood per day) 
= PIT - (PI X [IO0 - Hct X 0.9]/100 X 0.0015) 
The effect of transfemn saturation (S) was removed by converting 
TIU to iron-bearing transfemn uptake, and nonerythron uptake was 
subtracted" to obtain ETU: 
ETU (pmol/L whole blood per day) 
TIU X 10 (200 + 2.2 S) - 11 - ~ 
56 (200 + 6.4 S) 
The derivation of this formula is described e l se~he re .~  ETU was also 
corrected for abnormalities in blood volume by the ratio of measured 
to predicted blood volume. 
Epo Assay 
Circulating Epo levels were measured by two different radioim- 
munoassays (RIA). The first RIA is a modification of an assay pre- 
viously described in detail: and the second RIA is commercially 
available (Incstar Cow, Stillwater, MN). Both use recombinant human 
Epo (rHuEpo) for tracer and standards. Samples are incubated with 
rabbit anti-Epo serum for 3 days at 4°C (RIA # I )  or 2 hours at room 
temperature (RIA #2) before Epo tracer is added. After overnight 
incubation, goat antirabbit serum is added. After centrifugation, the 
unbound tracer is removed by decantation and the pellet is counted. 
Several samples had to be diluted I : 10. Thirty samples, with Epo 
concentrations ranging from 10 to 200 mU/mL, were measured by 
the two RIAs and no significant difference was found. Twelve control 
samples were run in each assay, with a between-assay coefficient of 
variation ranging from 10.3% to 14.1%. 
TfR Assay 
Human placental receptor-transfemn complex was purified as de- 
scribed elsewheret4 and injected repeatedly into rabbits. Serum IgG 
was isolated from rabbit ~ e r u m ' ~  and transferrin antibodies were re- 
moved by passing through a column of human difemc transfenin 
coupled to Affigel 15 (BioRad, Richmond, CA). Characterization of 
plasma TW and receptor antibody has been described e l s e ~ h e r e . ~ . ~  
An enzyme-linked immunosorbent assay (ELISA)5 with minor 
modifications to measure serum levels of TW was used. Immunoplates 
I with certificate of quality (Nunc Intermed, Roskilde, Denmark) 
were used. The aliquots of blanks, standards, and unknown samples 
were added using a Digiflex automatic pipetor (Micromedic System, 
Philadelphia, PA). Standards were diluted to between 5 and 100 ng/ 
mL and unknown sera were diluted 1:50 to 1:2,000 with 0.15 mol/ 
L phosphate-buffered saline (PBS; pH 7.4) containing 0.5% bovine 
serum albumin and 0.05% Tween 20. After color development, dif- 
ferential absorbance was read in dual wave length mode at 492 and 
690 in a Titertek Multiskan MCC/340 plate reader (Flow Labora- 
tories, Herts, UK). In drawing the calibration curve, allowance was 
made for the molecular weight of the transfemn molecule included 
in the receptor-transfemn complex by multiplying the protein content 
of the standard by 0.69. Each sample was run in triplicate. The be- 
tween-assay variability (coefficient of variation) was 7.2% when the 
same control sample was measured in each plate. 
Reticulocyte (retic) Index 
Blood smears were stained with new methylene blue and reticu- 
locytes in 1,000 cells were counted. The retic index was calculated 
after appropriate corrections for the subject's Hct and for reticulocyte 
shift, as described elsewhere.16 In the presence of anemia, a retic 
index greater than 3 is indicative of hemolytic anemia, and a retic 
index less than 2 of either a hypoproliferative or maturation abnor- 
mality. 
Statistical Methods 
Log transformed Epo, TW, and ETU values were used in statistical 
analyses. Student's t-tests, with pooled or separated variances as ap- 
propriate, were used to compare two groups. Analysis of variance 
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Fig 1. Relationship between EPO levels and Hct in groups of 
patients, each represented by its mean values. The regression line 
displays the relationship in reference subjects (see text). 1, 8-thal- 
assemia/HbE; 2, AMM; 3, AIHA; 4, spherocytosis; 5, hypoplastic 
anemia; 6, MDS; 7. HbH disease; 8, BMT; 9, MPD; 10, renal failure; 
1 1, renal failure on rHuEpo; 12, secondary PC; 13, relative PC; 14, 
PC of uncertain origin; 15, P V  16, normal subjects. 
(ANOVA), with Snedecor’s F-test or Welch’s test as appropriate, was 
used to compare more than two groups. The r correlation coefficients 
between Hct and log (Epo), log (TfR), and log (ETU) were computed 
in least squares regression equations. The slopes of the regression 
lines were tested for equality among groups by Student’s t-tests in an 
analysis of covariance. 
RESULTS 
Construction of Reference Regressions 
To construct the reference curves representing the rela- 
tionships between Hct on the one hand, and Epo, TW, and 
ETU on the other, only a subset of the subjects were consid- 
ered. Patients with polycythemia were excluded, because ab- 
normal marrow proliferation and excessive Epo production 
are often part of the pathophysiology of the disease. Patients 
with renal failure or hypoplastic anemia (as well as BMT 
patients) were excluded because of likely impairment of Epo 
production or reduced erythroid activity (see clinical criteria 
below). Patients with AMM, MDS, or advanced CML were 
also excluded because of the possibility of a component of 
relative erythroid hypoproliferation (see definition below) in 
many of them. Therefore, only the groups of normal subjects 
and of patients with other MPDs, AIHA, spherocytosis, 
P-thalassemia, and HbH disease were included. Among these 
groups, 3 patients were later excluded because Epo (in 2 
@-thalassemic patients) or TfR (in 1 AIHA patient) were well 
beyond 3 SD below the predicted value. 
As shown in Fig 1, two least squares regression equations 
40% and the other for Hct greater than 40%. This cutoff Hct 
was chosen because it allowed for the best correlation for Epo 
data and because of literature data indicating that beyond 
such a Hct there is little modification of Epo  level^.^,'^ For 
Hct less than 40%, the following regression ( r  = 33,  P = 
.OOOO) was obtained between Epo (mU/mL) and Hct (%): 
log (Epo) = 3.420 - (0.056 Hct). For Hct greater than 40%, 
the regression equation ( I  = .12, NS) was: log (Epo) = 1.3 11 
- (0.003 Hct). The reference regressions for TfR (Fig 2) and 
ETU were calculated in the same subjects, using the same 
cutpoint Hct. The following regressions were obtained with 
TW (pg/L): log (TW) = 6.146 - (0.057 Hct), when Hct is 
less than 40% (r = .75, P = .OOOO); and log (TW) = 4.079 - 
(0.008 Hct), when Hct is greater than 40% ( r  = .18, NS). The 
following regressions were obtained with ETU (pmol/L/d): 
log (ETU) = 4.06 I - (0.052 Hct), when Hct is less than 40% 
( r  = -.64, P = .OOOO); and log (ETU) = 2.086 - (0.006 Hct), 
when Hct is greater than 40% (r = -.15, NS). Thus the 
regression obtained for TfR and ETU had slopes very similar 
to those obtained with Epo (P > .1 for differences in slope). 
Based on these formulas, predicted log (Epo), log (TfR), and 
log (ETU) values were derived for each sample and O/P ratios 
of log (Epo), log (TW), or log (ETU) were calculated. Ninety- 
five percent confidence limits were calculated to define a range 
of reference values for individual O/P values. These limits 
were 0.80 to 1.22 for O/P Epo, 0.91 to 1.09 for O/P TfR, 
and 0.76 to 1.22 for O/P ETU. 
DeJinition of Patterns of Erythropoiesis 
The major patterns of erythropoiesis were defined exper- 
imentally, based on the Hct, O/P TW, and O/P Epo. The 
20 30 40 50 60 
Hct (%) 
Fig 2. Relationship between TfR levels and Hct in groups of pa- 
tients, each represented by its mean values. The regression line 
displays the relationship in reference subjects (see text). 1,B-thal- 
assemia/HbE; 2, AMM; 3, AIHA; 4, spherocytosis; 5, hypoplastic 
anemia; 6, MDS; 7, HbH disease; 8, BMT; 9, M P D  10. renal failure; 
1 1, renal failure on rHuEDo; 12, secondary PC; 13, relative PC; 14. 
between Epo and Hct were computed, one for Hct less than PC of uncertain origin; 15, PV; 16, normal subjects. 
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- Het (%) Epo (mU/mL) 
45.9 f 3.6 
51.8 f 5.9 
50.1 f 7.8 
50.7 f 4.2 
52.7 * 2.1 
38.2 L 3.6 
34.6 f 4.7 
29.6 f 5.0 
33.9 2 6.1 
21.6 f 3.4 
33.4 f 3.6 
34.3 * 4.8 
24.5 ? 5.0 
33.0 f 2.7 
34.3 f 7.0 
32.6 f 7.0 
14.1 f 2.8 
12.1 f 4.2 
10.1 ? 3.6 
52.9 t 77.9 
14.2 t 3.9 
21.6 f 20.3 
38.0 ? 20.3 
74.5 2 87.2 
88.9 f 78.7 
15.0 f 5.0 
12.7 k 4.1 
51.8 2 69.5 
80.4 f 39.7 
34.9 * 15.1 
44.6 -+ 20.4 
97.5 2 147.1 
TfR Gg/L) ETU (pmol/L/d) 
4,970 f 1,030 61 f 1 5  
7,280 f 2,480 77 f 20 
10,480 f 5.870 97 f 31 
7.780 +- 3,910 80 * 30 
4,840 + 890 81 +21 
5,370 f 1,140 76 * 65 
9 8 f  105 7,980 t 6,750 
8,050 f 2,270 133 lr 64 
4,OlOf 1,410 5 0 f  18 
2,610 f 1,060 40 f 28 
6,410 f 860 71 f 2 0  
2,450 f 1,000 63 f 36 
46,830 f 1 1,730 562 f 207 
23,250 f 5,760 235 2 106 
22,050 ? 1 1,040 506 f 303 
16,300 IT 7.270 235 f 133 
s (%) Ferritin (rg/L) 
30 f 8 95 f 74 
32 f 15 92 k 81 
1 8 f 9  4 0 2  17 
32 f 18 162 f 196 
35 f 8 135 f 103 
30 f 19 510f  1,070 
47 k 26 446 ? 708 
35 f 21 276 f 280 
60 k 23 550 k 530 
36 + 19 699 2 770 
23 k 6 189 * 217 
58 k 23 2,925 f 2,399 
57 f 24 656 f 809 
44 * 1 1  923 f 698 
33 * 13 535 f 635 
80 f 26 1,686 k 1,954 
Retic (%) 
2.1 f 1.2 
2.0 f 1 .o 
2.6 f 1.6 
2.6 f 3.0 
1.8 f 1.6 
2.0 * 1.3 
3.3 f 3.8 
3.9 * 2.6 
2.5 f 2.4 
2.1 f 1.0 
2.5 f 1 .O 
3.4 f 1.5 
1.7 f 1.3 
2.0 f 1.7 
4.7 f 1.5 
7.1 * 3.4 
retic index and TfR served to separate major patterns into 
variants. A normal pattern of erythropoiesis (pattern A) was 
defined by normal Hct, O/P Epo, and O/P TfR. The TfR 
value helped differentiate a variant of compensated hemolysis 
(pattern A2) in which TfR was increased, with a correspond- 
ing clinical picture of increased erythroid marrow cellularity 
and decreased RBC life span. 
The term “hyperdestruction” referred to an experimental 
diagnosis (pattern B) in which Hct was decreased and O/P 
Epo and O/P TfR were normal. The corresponding clinical 
diagnosis of increased RBC destruction and erythroid activity 
was based on the following criteria: (1 )  increased erythroid 
cellularity on marrow examination; (2) shortened RBC life 
span for a diagnosis of hemolysis. The retic index served to 
break this group down into two variants of “hemolysis” (pat- 
tern B 1) and “ineffective erythropoiesis” (pattern B3). When 
the retic index was between 2 and 3, this distinction could 
not be readily made (pattern B2). 
The term “intrinsic marrow hypoproliferation” referred 
to an experimental diagnosis (pattern C) defined by eryth- 
ropoietic activity inadequately low for the degree of anemia 
(decreased O/P TfR) in the presence of adequate Epo stim- 
ulation. Intrinsic marrow hypoproliferation could be absolute 
(decreased TfR), relative (increased TfR), or intermediate 
(normal TfR). In the first case, the experimental diagnosis 
was “hypoproliferative anemia” (pattern C3), with a corre- 
sponding clinical picture of reduced erythroid cellularity on 
marrow examination. In the second case, the experimental 
diagnosis was “mixed disorder of erythropoiesis” (pattern C l), 
ie, with both hyperdestruction and hypoproliferation com- 
ponents. Clinically, the erythroid marrow could be normal 
or hypercellular. In the third case (pattern C2), the meth- 
odology could not distinguish between “mixed disorder of 
erythropoiesis” and “hypoproliferative anemia”; such patients 
all showed a retic index of less than 3. 
The term “defective Epo production” referred to an ex- 
perimental diagnosis (pattern D) defined by erythropoietic 
activity inadequately low for the degree of anemia (decreased 
O/P TfR) because of inadequate Epo production (decreased 
O/P Epo). Defective Epo production could be simple (de- 
creased TfR), composite (increased TfR), or intermediate 
(normal TfR). As with pattern C, the experimental diagnoses 
were Epo-dependent “hypoproliferative anemia” (pattern 
D3), “mixed disorder of erythropoiesis” (pattern Dl), and 
indeterminate (pattern D2). The corresponding erythroid 
marrow should be respectively: hypocellular; normocellular 
or hypercellular; and normocellular or hypocellular. The retic 
index was always less than 3 in this group. 
“Experimental” Classification of Anemic Subjects 
Hematologic measure- 
ments are presented in Table 1. Epo, TfR, and ETU levels 
of each group were compared with values predicted from 
their Hct according to the reference regression equations de- 
fined above, and ratios of O/P Epo, TfR, ETU, and RCM 
are shown in Table 2. The figures illustrate the relationship 
between mean Hct and mean Epo (Fig I )  or mean TfR (Fig 
2) levels for the various groups of subjects, as compared with 
the predicted values. 
The 31 normal subjects had a mean (mean k SD) Hct of 
45.9% k 3.6% (range, 40% to 52% in men and 37% to 47% 
in women), a mean Epo of 14.1 k 2.8 mU/mL (range, 9.3 
to 23. I),  a mean TfR of 4,970 k 1,030 pg/L (range, 2,700 to 
7,650), and a mean ETU of 6 1 k 15 pmol/L/d (range, 32 to 
95). Their mean O/P Epo was 0.99 k 0.07 (range, 0.85 to 
1.17), their mean O/P TfR was 0.99 -t 0.03 (range, 0.91 to 
I .05), and their mean O/P ETU was 0.98 k 0.08 (range, 0.86 
Patients with renal failure had Epo levels normal in ab- 
solute value (Table l ) ,  but inadequate for the degree of ane- 
mia, as illustrated in Table 2 (decreased O/P Epo) and Fig 1 
(mean value well below the reference line). Those treated 
with recombinant Epo came closer to the line of prediction 
(Fig 1). All other groups of anemic subjects had increased 
Epo values as compared with normal subjects (Table 1). This 
increase was appropriate for the degree of anemia, as shown 
Analysis of groups of subjects. 
to 1.13). 
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Table 2. Ratios of Observed to Predicted Values (mean f SD) in Groups of Subjects 

































1.03 f 0.08 
1.34 f 0.20' 
1.36 f 0.28$ 
1.37 f 0.33" 
0.92 f 0.17$ 
0.79 f 0.14t 
0.75 f 0.17t 
1.1 7 f 0.09" 
0.85 f 0.23$ 
0.53 f 0.09t 
0.80 f 0.1 O t  
NA 
NA 
0.84 f 0.15' 
0.64f 0.13t 
0.91 f 0.08 
0.99 f 0.07 
0.93 f 0.12 
0.85 f 0.1 1' 
1.31 f 0.37% 
1.01 f0.12 
1 .oo f 0.1 9 
1 .OO f 0.15 
0.93 f 0.23 
1.02 f 0.29 
0.53 f 0.10t 
0.72 f 0.16t 
1.01 f 0.21 
0.94 f 0.13 
1.03f0.11 
1.04 f 0.1 2 
1.05 f 0.10 
0.99 5 0.03 
1.05 f 0.05t 
1.08 f 0.09" 
1.05 f 0.06' 
1.01 f 0.02 
0.94 f 0.05t 
0.92 f 0.04t 
0.88 f 0.05t 
0.85 f 0.06t 
0.69 f 0.04t 
0.90 f 0.06' 
0.98 f 0.06 
1.05 f 0.04' 
1.01 fO.04 
0.98 f 0.09 
0.81 f 0.06t 
0.98 f 0.08 
1.06 f 0.09' 
1.1OfO.11" 
1.07 f 0.08' 
1.09 f 0.07" 
0.86 f 0.16' 
0.80 f 0.14t 
0.83 f 0.15t 
0.75 f 0.14t 
0.80 f 0.12t 
0.78 f 0.12t 
0.97 f 0.06 
1.04 f 0.09 
1.1OfO.08' 
1.01 f 0.14 
0.51 f 0.15t 
P values are given for comparison with normal subjects. 
Abbreviation: NA, not available. 
"P < .01. 
tP< ,001. 
SP < .05. 
in Fig 1 (all groups were near the line of prediction) and in 
Table 2 (O/P Epo close to 1 .O). 
Patients with AIHA, spherocytosis, @-thalassemia, and 
HbH disease had TfR and ETU values considerably elevated 
as compared with normal subjects (Table I), indicating an 
increased erythroid marrow activity in response to an in- 
creased Epo stimulation. The distinction between hemolysis 
and ineffective erythropoiesis could be made by a retic index 
of greater than 3 and less than 2, respectively. 
On the other hand, only the BMT, hypoplastic anemia, 
and renal failure groups had decreased TfR values (Table 1). 
They were also the ones that fell the farthest below the ref- 
erence line (Fig 2) and had the lowest O/P TfR and O/P ETU 
(Table 2). Therefore, the anemia in these groups appeared 
to be a consequence of decreased erythroid activity, either 
because of reduced Epo production (renal failure) or intrinsic 
erythroid marrow hypoproliferation (BMT and hypoplastic 
anemia). 
Patients with MDS or AMM had elevated TfR levels (Table 
l), demonstrating that their anemia was not primarily due 
to reduced erythroid activity. However, their level of eryth- 
ropoiesis remained insufficient for the degree of anemia (Table 
2 and Fig 2). This indicated that, despite adequate Epo stim- 
ulation, there was a hypoproliferative component to their 
anemia. Hence, the pathophysiology of their anemia was 
mixed, ie, a combination of hyperdestruction and hypopro- 
liferation. 
Individual patients were 
classified according to their experimental pattern of eryth- 
ropoiesis. Table 3 discloses typical cases illustrating the var- 
ious patterns, whereas Table 4 dissects out each clinical group 
into experimental diagnostic groups. All normal subjects had 
a normal pattern of erythropoiesis (pattern A 1). Of 1 1 patients 
with AIHA, 7 had typical hemolysis (pattern Bl), 1 had an 
intermediate retic index (pattern B2), 2 had the variant nor- 
mal pattern with increased TfR (pattern A2), indicating that 
hemolysis was completely compensated by increased ery- 
throid activity, and one had an important intrinsic marrow 
hypoproliferative component (pattern C l), due to metastatic 
breast cancer. Patients with spherocytosis had typical he- 
molysis (pattern Bl), except for one who had returned to 
normal erythropoiesis (pattern A 1 )  after splenectomy. Pa- 
tients with @-thalassemia or HbH disease had typical ineffec- 
tive erythropoiesis (pattern B3). However, in one HbH pa- 
Analysis of individual patients. 
Table 3. Some Typical Cases and Characteristic Exceptions to the Patterns of En/thropoiesis 
Pattern of ENthrODOieSiS Clinical Diaanosis Hct OIPTfR 
Normal ( A I )  Normal subject 48.8 1.00 
Hemolysis (BI)  AlHA 31.1 1.00 
Ineffective erythropoiesis (B3) HbH disease 30.0 0.99 
Intrinsic marrow hypoproliferation: hypoproliferative anemia (C3) Aplastic anemia 25.2 0.70 
Intrinsic marrow hypoproliferation: mixed disorder of erythropoiesis ( C l )  AMM 23.0 0.84 
Defective Epo production: hypoproliferative anemia (D3) Renal failure 20.6 0.68 
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Table 4. Number of Individual Patients by Clinical Diagnosis in Each Pattern of Erythropoiesis 
C D 
A B Intrinsic Marrow Defective Epo 
Normal Hyperdestruction Hypoproliferation Production 
Variant 1 2 1 2 3 1 2 3 1 2 3 
Hct N Low Low Low 
O/P TfR N-(High) N Low Low 
O/P Epo N-(High) N N Low 
Tf R N High High N Low High N Low 
Retic index >3 2-3 <2 
Erythroid cellularity High High High High High-N N-Low Low High-N N-Low Low 

















1 1  2 
15 
5 1  
9 1’ 
1 1  
10 
1 1  2t 











7 5 1 2 
6 1 2 
4 1 1  
3 
1 6 1 
2 
1 
*High O/P Epo. 
tHigh O/P TfR. 
tient, a high retic index suggested predominantly peripheral 
hemolysis (pattern Bl) instead, and in two P-thalassemia pa- 
tients, a component of defective Epo stimulation (pattern 
Dl) was identified. Renal failure was typically associated with 
Epo-dependent hypoproliferative anemia (pattern D3), 
whereas a minority of them managed to achieve normal (al- 
though insufficient) TfR levels (pattern D2). Treatment with 
recombinant Epo reversed this pattern completely in 1 patient 
(pattern Al). In another patient, exogenous Epo produced 
the apparently aberrant situation of normal erythropoiesis 
(O/P TfR 0.94) despite insufficient (endogenous) Epo stim- 
ulation (O/P Epo 0.65). BMT was mostly associated with 
hypoproliferative anemia of marrow origin (pattern C3), 
whereas 1 patient had an additional component of defective 
Epo production (pattern D2). One BMT patient had nor- 
malized erythropoiesis (pattem A 1) through an inappropriate 
increase of Epo production (O/P Epo 1.47) induced by lung 
disease. The majority of patients with hypoplastic anemia 
had hypoproliferative anemia, either by intrinsic marrow de- 
fect (patterns C2 and C3) or by defective Epo production 
(pattern D3) in a case of hypothyroidism or a case of anemia 
of chronic disorder. In addition, two patients in this group 
had completely normalized at the time of the study (pattern 
Al) .  Many patients with MPD had a normal pattern (pattern 
Al), but ineffective erythropoiesis (pattern B3) and a com- 
ponent of intrinsic marrow hypoproliferation (pattern C2) 
were often encountered. Ineffective erythropoiesis (pattern 
B3) was the predominant mechanism of anemia in MDS, 
but hemolysis (pattern BI) and intrinsic marrow hypopro- 
liferation (patterns C1 and C2) were also seen. In AMM, 
hyperdestruction (pattern B), intrinsic marrow hypoprolifer- 
ation (pattern C), and defective Epo production (pattern D) 
were all observed as the primary mechanism of anemia, as 
well as in combination. 
“Experimental” Clussijication of Polycythemic Subjects 
Groups of polycythemia patients had elevated Hct (Table 
1) and RCM (Table 2). Patients with a clinical diagnosis of 
relative PC had normal (Table 1) and appropriate (Figs 1 
and 2 and Table 2) Epo and TfR levels. Patients with a clinical 
diagnosis of absolute PC had increased TW and ETU (Table 
1) in the presence of high O/P Epo in the case of secondary 
PC, or a clinical diagnosis of normal to low to normal O/P 
Epo in the case of PV or uncertain PC (Fig 1 and Table 2). 
Clinical diagnosis of PC was also compared with experimental 
diagnosis on an individual basis. Inappropriately high Epo 
(increased O/P Epo) was considered characteristic of second- 
ary PC, whereas inappropriately high TfR (increased O/P 
TfR) in the presence of normal to low to normal O/P Epo 
was considered characteristic of PV. Eight patients had Hct 
and RCM within normal limits at time of investigation, and 
6 had increased Hct but normal RCM because of previous 
therapy. O/P Epo and O/P TfR were normal in all of them. 
Among patients who were polycythemic at the time of in- 
vestigation, there was no experimental confusion between 
PV and secondary PC. Among patients with uncertain PC, 
two were identified as having likely PV (increased O/P TfR 
with normal, to low to normal O/P Epo). 
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Correlations Bet ween Parameters of Eryrhropoiesis 
There was an excellent correlation between Hct and O/P 
RCM ( r  = .83, P < .OOOl), as well as between ETU and TfR 
levels (r = 32,  P < .O001). Expressing ETU values in micro- 
moles per day and TfR in micrograms, by multiplying con- 
centrations by blood or plasma volumes, respectively, did 
not alter the correlation ( r  = 3 1 ,  P < .OOOI) between the 
two measurements oferythropoiesis. This is illustrated in Fig 
3, in which each group of subjects is represented by its mean 
ETU and TfR values. In polycythemia patients, there was a 
positive correlation between TfR and Hct ( r  = .42, P < .05) 
as well as between TfR and RCM ( r  = .63, P < .001). In 
contrast to other groups of patients, there was a positive re- 
lationship between Epo levels and Hct in patients with renal 
failure ( r  = .46, P < .05). The overall correlations between 
Epo levels and TfR levels ( r  = .45, P < .001) or ETU ( r  = 
.42, P < .001) were relatively weak because they reflected 
many different patterns of erythropoiesis. 
DISCUSSION 
In the present study, we investigated the pathophysiology 
of RBC production in a large group of normal, anemic, or 
polycythemic subjects. The RCM was quantitated by direct 
isotopic measurement, Epo stimulation by serum Epo levels, 
and total marrow erythropoietic activity by the ferrokinetic 
measurement of the ETU, serum TfR levels, and retic index. 
Instead of only quantitating Epo levels and erythropoiesis in 
absolute terms, we also evaluated them in relation to the 
degree of anemia or PC, and expressed results as a ratio of 
observed to predicted values. These quantitative measure- 
ments were supplemented by the qualitative evaluation of 
erythroid cellularity on marrow examination. The study of 
anemic subjects is based on a simple model of the regulation 
of erythropoiesis, ie, the RCM determines Epo production, 
which stimulates erythropoietic activity. If this model of 






Fig 3. conelation between TfR levels and ETU 
in groups of patients. each represented by its mean 
values. The shaded area represents a proportional 
relationship, and its limits were obtained by drawing 
a line through mean f SD TfR levels and ETU values 
in normal subjects (open circle). 1, fl-thalassemia/ 
HbE; 2. AMM: 3. AIHA; 4, spherocytosis; 5, hy- 
poplastic anemia; 6. MDS 7, HbH disease; 8, BMT; 
9. MPD; 10. renal failure; 11, renal failure on 
rHuEpo: 12. secondary PC; 13. relative PC: 14, PC 
of uncertain origin; 15, PV. ETU is overestimated 




the relationship between Hct and erythropoiesis should be 
similar to the one between Hct and Epo. If this is the case, 
then (1) an inverse relationship should be observed between 
Epo and Hct, as well as between TfR and Hct; (2) the regres- 
sion lines of log(Epo) versus Hct and of log(TfR) versus Hct 
should have similar slopes; and (3) Epo and TfR values pre- 
dicted from the regressions should then not be different from 
observed values. These three conditions were indeed fulfilled. 
First, after excluding groups of patients whose anemia was 
known to be associated with renal failure and/or a hypopro- 
liferative component, an excellent inverse correlation was 
observed between Hct and Epo on the one hand, and between 
Hct and TfR (as well as ETU) on the other. Second, the slope 
of the regression of TfR (as well as ETU) versus Hct was very 
similar to the slope of the regression of Epo versus Hct. Third, 
Epo and TfR (as well as ETU) values predicted from the 
regression equations were quite comparable to observed val- 
ues in most groups of subjects (Table 2 and Figs I and 2). A 
predictable exception for Epo was the group of renal failure 
patients (O/P Epo 53% of predicted), whereas those treated 
with recombinant Epo came closer to the line of prediction 
(O/P Epo 72% of predicted) (Fig 1). For TfR, the groups of 
patients whose primary cause of anemia was decreased ery- 
throid activity fell the farthest below prediction, whereas pa- 
tients with MDS and AMM also had a hypoproliferative 
component to their anemia. All this is in keeping with our 
knowledge of the pathophysiology of these hematologic dis- 
orders. 
When normal individuals are phlebotomized while iron 
supply is adequate, they are able to sustain an erythropoietic 
activity 3 to 5 times normal.” This will translate into TfR 
levels increased in proportion to Epo stimulation. However, 
in the presence of erythroid hypoproliferation, TfR values 
will be lower than expected from the level of Epo stimulation. 
In the current study, only 20 patients had purely hypopro- 
liferative anemia (decreased TfR), whereas all others had 
 
1 €ru (X normal) 10 
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normal or elevated TfR values. However, when examined 
relative to the degree of anemia, 42 additional patients were 
found to have varying degrees of erythroid marrow hypo- 
proliferation, including 16 patients who actually had elevated 
serum TW levels. Therefore, any measurement of erythro- 
poiesis not related to the degree of anemia could grossly over- 
estimate marrow proliferative capacity. Several attempts have 
been made previously to address this problem. Using so- 
phisticated computer analysis of ferrokinetic data, a distinc- 
tion could be made between anemic patients with high and 
low potential erythropoiesis on the basis of a value for total 
erythropoiesis higher or lower than 4 times basal, and a more 
precise rule could be derived by defining a decision boundary 
relative to the hemoglobin concentration.’’ 
Examining serum Epo and TfR in relation to the degree 
of anemia had the further advantage of identifying patients 
with a “mixed disorder of erythropoiesis,” ie, individuals with 
a hypoproliferative component combined with a component 
of hyperdestruction (hemolysis or ineffective erythropoiesis). 
Thus, besides typical patterns of erythropoiesis (Table 3), 
many patients had a composite pathophysiology. As shown 
in ferrokinetic studies,” dissecting out groups of patients to 
examine individual patterns of erythropoiesis (Table 4) 
showed that the mechanism of anemia may be similar among 
patients with different diseases, but can also vary much among 
patients with the same clinical disorder. For instance, among 
patients with a clinical diagnosis of hemolytic anemia (spher- 
ocytosis or AIHA), 1 became normal after splenectomy, 2 
compensated completely for the hyperdestruction, and 1 had 
a component of hypoproliferation. Besides patients with renal 
failure, defective Epo production was also observed in many 
patients, including some with P-thalassemia/HbE?’ AMM, 
MPD, and hypoplastic anemia or after BMT (Table 4). 
Apparently aberrant patterns could also find an explana- 
tion. For instance, a patient with renal failure had normal 
erythropoietic activity despite inadequate endogenous Epo 
production because of administration of exogenous recom- 
binant Epo, a BMT patient had normalized erythroid activity 
through excessive Epo stimulation induced by chronic hy- 
poxia, and 2 patients had elevated TW levels despite an oth- 
erwise normal pattern of erythropoiesis because they had fully 
compensated for a hemolytic process. 
The identification of different pathophysiologic compo- 
nents could have important implications for the treatment 
of the anemia in individual patients with an otherwise well- 
defined clinical diagnosis. For instance, treatment with 
rHuEpo would probably be unsuccessful in the case of a 
purely hyperdestructive anemia, but would be more likely to 
be effective when a component of defective Epo production 
or a purely hypoproliferative anemia have been identified. 
In the case of diseases such as AMM, MDS, or MPD, in 
which the pathophysiology of the anemia is often composite, 
a careful analysis could separate patients into poor and good 
candidates for Epo therapy. This remains to be shown pro- 
spectively. 
The proposed model of erythropoiesis has several limita- 
tions. First, the exactness of each measurement has its own 
limits; an apparent inadequacy of Epo production could in 
fact result from better tissue oxygenation with altered oxygen 
dissociation curves, iron deficiency could cause some ele- 
vation of TfR levels not related to erythropoiesis,2’ and the 
retic count is hampered by imprecision and can be at best 
considered as a semiquantitative measurement. Second, while 
a mixed disorder of erythropoiesis can be readily identified 
in patients with low O/P TfR but increased TfR value, it is 
more difficult to distinguish a component of hyperdestruction 
from a situation of blunted marrow response to increased 
Epo stimulation without hyperdestruction when TfR level is 
normal. However, when we carefully analyzed patterns of 
erythropoiesis in relation to clinical diagnosis (Table 4), it 
became apparent that when TW was normal and Epo pro- 
duction inadequate (decreased O/P Epo), blunted marrow 
responsiveness was by far more likely, whereas a component 
of hyperdestruction was more likely when O/P Epo was nor- 
mal. 
A third difficulty is encountered when one attempts to 
separate hemolysis from ineffective erythropoiesis, as both 
are characterized by a low Hct, elevated TfR, and normal 
O/P TfR and O/P Epo. After appropriate corrections are 
made,I6 the retic index can be of great help in most cases. 
While the RBC life span can be evaluated by isotopic meth- 
ods, there is no gold standard with which to measure inef- 
fective erythropoiesis. Sophisticated computer analyses of 
ferrokinetic data have attempted to quantitate ineffective 
erythropoiesis, but some aspects of iron exchange remained 
impossible to resolve in these calculations, particularly the 
separation of wastage iron of erythropoiesis from iron taken 
up by parenchymal Some cases presenting condi- 
tions defined as dyserythropoietic can also show a component 
of peripheral hemolysis, while so-called hemolytic anemias 
can be characterized by varying degrees of ineffective eryth- 
ropoiesis.2”26 Therefore, the erythropoietic pattern may de- 
pend on the stage oferythroid development at which destruc- 
tion occurs and a clear distinction between ineffective 
erythropoiesis and peripheral hemolysis may not always be 
possible. 
Finally, the model does not contribute much to the ap- 
proach to patients with PC. The RCM correlated positively 
with TfR much better than with the Hct, suggesting a caus- 
ative and quantitatively valid link between the RCM and 
erythropoiesis as measured by the TfR level. However, a typ- 
ical pattern of increased O/P TW with (secondary PC) or 
without (PV) increased O/P Epo was not frequently observed. 
Therefore, a correct diagnosis of PC should be based on an 
RCM determination (and not a Hct) and other standard cri- 
t e ~ i a . ~  Serum Epo could be useful in identifying patients with 
secondary PC, although many of them have normal val- 
u e ~ , ~ , ~ ~ - ~ ~  and serum TW in making a diagnosis of PV in 
some patients with PC of uncertain origin, as illustrated in 
two of our patients. 
Given these limitations of a model incorporating the Hct, 
serum Epo, serum TfR, and retic index, it could be possible 
to substitute other measurements. The isotopic measurement 
of the RCM gives a better idea of the total number of RBCs 
than the Hct, particularly in the case of splenomegaly or al- 
tered plasma volume. Although a direct evaluation of the 
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RCM is indispensable in the diagnosis of PC, the Hct remains 
sufficient for most practical purposes in a situation of anemia. 
While we do not have any equivalent tool to replace serum 
Epo, erythropoiesis could be approached by other methods 
than TW, such as the marrow erythroid cellularity, retic in- 
dex, and ETU. 
The present model only deals with the pathophysiology of 
anemia and has no pretension to replace a marrow exami- 
nation to identify specific clinical disorders or to recognize 
iron deficiency along with a serum ferritin level. A marrow 
sample can also be used to evaluate overall erythroid cellu- 
larity, but can only describe it in a semiquantitative fashion 
as normal, hypocellular, or hypercellular. The erythropoietic 
response to anemia cannot be measured quantitatively from 
the marrow alone, and a hypoproliferative component cannot 
be identified in patients with normocellular or hypercellular 
erythroid marrow. Furthermore, there are many instances in 
which a representative sample cannot be obtained because 
of nonhomogeneous marrow distribution, or in which an 
abnormally expanded white blood cell population precludes 
a meaningful interpretation of the erythroid/myeloid ratio 
and the erythroid mass. 
As illustrated in Table 1, the retic percentage does not 
provide a quantitative evaluation of total erythropoiesis, as 
the majority of the groups of patients were indistinguishable 
from normal individuals and several groups of patients char- 
acterized by hypoproliferative anemia as defined here had 
elevated counts. The retic count showed no correlation with 
the Hct, TW, or ETU. After corrections were applied, a retic 
index greater than 3 was rarely encountered outside the AIHA 
and spherocytosis groups, although many of the patients had 
increased erythropoietic activity. Patients with a hypoprolif- 
erative component, ineffective erythropoiesis, or both re- 
mained indistinguishable. Therefore, with the exception of 
patients with a purely hemolytic anemia, the retic count and 
index alone do not provide a quantitative evaluation of 
erythropoiesis. However, when used in conjunction with 
quantitative measurements, they provide information com- 
plementary to TfR, particularly when one desires to separate 
hemolysis from ineffective erythropoiesis. 
When transferrin saturation decreases below 16% or the 
plasma radioiron t-% is less than 30 minutes, ferrokinetic 
measurements are no longer valid.3o On the other hand, when 
plasma iron is elevated, the presence of nontransfemn-bound 
iron3L,32 whose turnover is not related to the erythron but to 
the hepatocyte33 can overestimate erythropoiesis. This prob- 
lem was probably encountered in our BMT patients (Fig 3). 
Because its calculation is based on three separate measure- 
ments (plasma iron, radioiron t-%, and Hct), the ETU is more 
vulnerable to experimental error than TW levels and, indeed, 
in the present study its coefficient of variation was higher in 
normal subjects as well as in patients, its correlation with 
Hct weaker, and its 95% confidence limits wider. Although 
the overall correlation between ETU and TW was excellent, 
the greater precision and simpler methodology of the TW 
determination should make it the method of choice for es- 
timating erythroid activity. 
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